Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Louis Bourgeois

Showing results (61-70 of 70) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 70 results.
NPJ Vaccines|September 5, 2019
Interrogation of a live-attenuated enterotoxigenic <i>Escherichia coli</i> vaccine highlights features unique to wild-type infectionSubhra Chakraborty, Arlo Randall, Tim J Vickers, et al.
The Journal of Infectious Diseases|May 26, 2018
Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine DevelopmentSubhra Chakraborty, Arlo Randall, Tim J Vickers, et al.
The Lancet. Infectious Diseases|November 24, 2019
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trialFirdausi Qadri, Marjahan Akhtar, Taufiqur R Bhuiyan, et al.
Vaccine|November 30, 2023
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshopsShahida Baqar, Aurelio Bonavia, A Louis Bourgeois, et al.
Vaccine|November 29, 2023
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentationsSoumalya Banerjee, Eileen M Barry, Shahida Baqar, et al.
Vaccine|November 27, 2018
Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analysesMarjahan Akhtar, Mohiul I Chowdhury, Taufiqur R Bhuiyan, et al.
The Journal of Clinical Investigation|July 2, 2019
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severityPardeep Kumar, F Matthew Kuhlmann, Subhra Chakraborty, et al.
The Journal of Clinical Investigation|May 18, 2018
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severityPardeep Kumar, F Matthew Kuhlmann, Subhra Chakraborty, et al.
Lancet (London, England)|June 17, 2008
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trialSarah A Frech, Herbert L Dupont, A Louis Bourgeois, et al.
Frontiers in Bacteriology|November 27, 2025
Safety and immunogenicity of a recombinant double-mutant heat-labile toxin derived from enterotoxigenic <i>Escherichia coli</i> in healthy Bangladeshi adults delivered by three different routesTaufiqur Rahman Bhuiyan, Farhana Khanam, Salima Raiyan Basher, et al.
Pageof 7

Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
NPJ Vaccines|September 5, 2019
Interrogation of a live-attenuated enterotoxigenic <i>Escherichia coli</i> vaccine highlights features unique to wild-type infectionSubhra Chakraborty, Arlo Randall, Tim J Vickers, et al.
The Journal of Infectious Diseases|May 26, 2018
Human Experimental Challenge With Enterotoxigenic Escherichia coli Elicits Immune Responses to Canonical and Novel Antigens Relevant to Vaccine DevelopmentSubhra Chakraborty, Arlo Randall, Tim J Vickers, et al.
The Lancet. Infectious Diseases|November 24, 2019
Safety and immunogenicity of the oral, inactivated, enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi children and infants: a double-blind, randomised, placebo-controlled phase 1/2 trialFirdausi Qadri, Marjahan Akhtar, Taufiqur R Bhuiyan, et al.
Vaccine|November 30, 2023
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of breakout workshopsShahida Baqar, Aurelio Bonavia, A Louis Bourgeois, et al.
Vaccine|November 29, 2023
The 2022 Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference: Summary of abstract-based presentationsSoumalya Banerjee, Eileen M Barry, Shahida Baqar, et al.
Vaccine|November 27, 2018
Evaluation of the safety and immunogenicity of the oral inactivated multivalent enterotoxigenic Escherichia coli vaccine ETVAX in Bangladeshi adults in a double-blind, randomized, placebo-controlled Phase I trial using electrochemiluminescence and ELISA assays for immunogenicity analysesMarjahan Akhtar, Mohiul I Chowdhury, Taufiqur R Bhuiyan, et al.
The Journal of Clinical Investigation|July 2, 2019
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severityPardeep Kumar, F Matthew Kuhlmann, Subhra Chakraborty, et al.
The Journal of Clinical Investigation|May 18, 2018
Enterotoxigenic Escherichia coli-blood group A interactions intensify diarrheal severityPardeep Kumar, F Matthew Kuhlmann, Subhra Chakraborty, et al.
Lancet (London, England)|June 17, 2008
Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trialSarah A Frech, Herbert L Dupont, A Louis Bourgeois, et al.
Frontiers in Bacteriology|November 27, 2025
Safety and immunogenicity of a recombinant double-mutant heat-labile toxin derived from enterotoxigenic <i>Escherichia coli</i> in healthy Bangladeshi adults delivered by three different routesTaufiqur Rahman Bhuiyan, Farhana Khanam, Salima Raiyan Basher, et al.
Pageof 7